using the terms ceftobiprole, medocaril, BAL 5788, RO-5788, BAL 9141, RO 63-9141, pyrrolidinone cephalosporin, MRSA, complicated skin and skin-structure infections (cSSSIs), community-acquired ...

Purpose. The pharmacology, antimicrobial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of ceftobiprole are reviewed. Conclusion. Ceftobiprole is a ...

Innoviva Specialty Therapeutics, Inc., ("IST") a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered ...

We are very pleased with our collaboration with Innoviva Specialty Therapeutics for the commercialization of Zevtera in the US. The company is a highly committed, focused and capable partner that ...

Basilea Pharmaceutica will finally be able to bring its antibiotic ceftobiprole to the US market ... acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial ...

Basilea will seek approval of ceftobiprole for SAB as well as acute bacterial skin and skin structure infection (ABSSSI) based on the results of the earlier TARGET study which showed non ...